Base de dados : MEDLINE
Pesquisa : C23.888.942.343 [Categoria DeCS]
Referências encontradas : 1780 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 178 ir para página                         

  1 / 1780 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771423
[Au] Autor:Chrzan R; Panek W; Kuijper CF; Dik P; Klijn AJ; de Mooij KL; de Jong TP
[Ad] Endereço:Department of Pediatric Urology, University Children's Hospital AMC/EKZ, Amsterdam, The Netherlands; Department of Pediatric Urology, UMC/WKZ, Utrecht, The Netherlands. Electronic address: r.chrzan@amc.nl.
[Ti] Título:Short-term Complications After Pyeloplasty in Children With Lower Urinary Tract Anomalies.
[So] Source:Urology;100:198-202, 2017 Feb.
[Is] ISSN:1527-9995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate whether children with lower urinary tract (LUT) anomalies are at greater risk for postoperative complications after laparoscopic pyeloplasty stented with a double-J catheter (JJC). MATERIALS AND METHODS: Prospectively collected data of laparoscopic pyeloplasty (LP) performed between 2006 and 2015 were analyzed. Inclusion criteria are (1) toilet-trained child and (2) unilateral dismembered pyeloplasty stented with a JJC done by the same surgeon. Our pyeloplasty protocol includes cystoscopy and retrograde pyelography. JJC is left in for 3weeks. Asymptomatic patients with infravesical LUT anomalies (a-LUTA) and those with history of LUT symptoms (LUTS) were identified. Any short-term complication was classified according to Clavien-Dindo. Fisher's exact test was used for statistical analysis. RESULTS: Fifty-four children (mean 9.8 years) were included. Ten of 54 patients had LUTS. In 4 of those 10, anatomical infravesical anomaly was found during cystoscopy. Accidental urethral anomaly was found in 11 patients (a-LUTA). The control group (CG) consisted of 33 patients. Postoperative hospital stay ranged from 1 to 8 days (mean 2 days). Overall complication rate was 8 of 54 (14%). Grade 1 complications occurred in 3 patients in the CG. Five patients had grade 3 complications (2 needed replacement of bladder catheter, and 3 had diversion of the upper tract). Those problems occurred in 1 of 10 patients with LUTS and 3 of 11 patients with a-LUTA compared to 1 of 33 in the CG. This difference was statistically significant (P < .05). CONCLUSION: Careful history should be taken in toilet-trained children before pyeloplasty. If any infravesical abnormality is discovered, internal diversion should probably be avoided. Special attention must be paid to bladder function in the postoperative period.
[Mh] Termos MeSH primário: Pelve Renal/cirurgia
Laparoscopia/efeitos adversos
Complicações Pós-Operatórias/epidemiologia
Procedimentos Cirúrgicos Reconstrutivos/efeitos adversos
Obstrução Ureteral/cirurgia
Anormalidades Urogenitais/cirurgia
[Mh] Termos MeSH secundário: Doenças Assintomáticas
Criança
Cistoscopia
Feminino
Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/cirurgia
Masculino
Stents
Obstrução Ureteral/etiologia
Urografia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  2 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351556
[Au] Autor:Li J; Tian Y; Guo S; Gu H; Yuan Q; Xie X
[Ad] Endereço:Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
[Ti] Título:Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.
[So] Source:PLoS One;13(1):e0191469, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. However, old dogs (>6 years) are expensive and not all old dogs develop BPH. So it is necessary to develop more accessible animal models for drug efficacy evaluation. Here we describe the development of testosterone-induced BPH models in both rats and young adult dogs and their applications in the in vivo evaluation of α1-AR antagonist. The BPH rats and dogs induced by chronic testosterone treatment have significantly increased micturition frequency and reduced mean voided volume, very similar to the clinical symptoms of BPH patients. Silodosin, an α1-AR antagonist, significantly reduces the urinary frequency and increases the voided volume in BPH model animals in a dose-dependent manner. The results demonstrate that testosterone-induced BPH rat and dog models might provide a more efficient way to evaluate micturition behavior in anti-BPH drug studies.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Hiperplasia Prostática/induzido quimicamente
Testosterona/toxicidade
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Idoso
Animais
Modelos Animais de Doenças
Cães
Avaliação Pré-Clínica de Medicamentos
Feminino
Seres Humanos
Indóis/uso terapêutico
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Ratos
Ratos Sprague-Dawley
Testosterona/administração & dosagem
Micção/efeitos dos fármacos
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Indoles); 0 (Urological Agents); 3XMK78S47O (Testosterone); CUZ39LUY82 (silodosin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191469


  3 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202586
[Au] Autor:Ladi-Seyedian SS; Nabavizadeh B; Sharifi-Rad L; Kajbafzadeh AM
[Ad] Endereço:a Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center , Tehran University of Medical Sciences , Tehran , Iran.
[Ti] Título:Pharmacological treatments available for the management of underactive bladder in neurological conditions.
[So] Source:Expert Rev Clin Pharmacol;11(2):193-204, 2018 Feb.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Underactive bladder (UAB) is a common cause of lower urinary tract dysfunction which has an increasing incidence with aging. It is characterized as an incompetent detrusor contraction with reduced strength and/or duration to completely empty the bladder. UAB is observed in both men and women. The exact definition, classification, and pathophysiological mechanism responsible for UAB is still debatable, however neurologic, myogenic, and iatrogenic causes are explained. The symptom complex related to UAB includes hesitancy, diminished sensation of bladder filling, a slow urinary stream, increased post-void residue, and etc. Areas covered: We reviewed the current understanding of UAB with special focus on pharmacological treatments and potential pharmacotherapy options particularly in neurological conditions. Also, the definition, etiology, symptoms, diagnosis and management of UAB were discussed in this review. Expert commentary: The underlying mechanism of UAB is not clear yet. Therefore; the lack of efficient pharmacotherapies is evident in such patients. Prior to any decision for pharmacological or surgical interventions, the underlying causes of UAB and detrusor impairment in each patient should be distinguished. Future researches need to address the exact dynamics of detrusor contraction and the muscular and neurological contributors to UAB.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Doenças da Bexiga Urinária/tratamento farmacológico
Bexiga Urinaria Neurogênica/tratamento farmacológico
[Mh] Termos MeSH secundário: Fatores Etários
Envelhecimento
Animais
Feminino
Seres Humanos
Incidência
Sintomas do Trato Urinário Inferior/diagnóstico
Sintomas do Trato Urinário Inferior/fisiopatologia
Masculino
Fatores de Risco
Doenças da Bexiga Urinária/diagnóstico
Doenças da Bexiga Urinária/fisiopatologia
Bexiga Urinaria Neurogênica/diagnóstico
Bexiga Urinaria Neurogênica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1411801


  4 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419682
[Au] Autor:Kim JI; Choi TY; Jun JH; Kang H; Lee MS
[Ad] Endereço:Division of Acupuncture & Moxibustion Medicine, Kyung Hee Korean Medicine Hospital, Kyung Hee University, Seoul.
[Ti] Título:Acupuncture for management of lower urinary tract symptoms in Parkinson's disease: A protocol for the systematic review of randomized controlled trials.
[So] Source:Medicine (Baltimore);97(6):e9821, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acupuncture is claimed to improve the lower urinary tract symptoms (LUTS). Currently, no systematic reviews are performed for acupuncture on LUTS in patients with Parkinson's diseases (PD). This review aims to evaluate the current evidence on the efficacy of acupuncture for the management of LUTS in PD. METHODS AND ANALYSES: Eleven databases will be searched from their inception. These include PubMed, AMED, EMBASE, the Cochrane Library, 6 Korean medical databases, and 1 Chinese medical database. Study selection, data extraction, and assessment will be performed independently by 2 researchers. Risk of bias will be assessed with the Cochrane risk of bias assessment tool. ETHICS AND DISSEMINATION: Ethical approval will not be required, given that this protocol is for a systematic review. The systematic review will be published in a peer-reviewed journal and disseminated both electronically and in print. The review will be updated to inform and guide healthcare practice and policy. TRIAL REGISTRATION NUMBER: PROSPERO 2018 CRD42018083857.
[Mh] Termos MeSH primário: Terapia por Acupuntura/métodos
Sintomas do Trato Urinário Inferior
Doença de Parkinson/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
[Mh] Termos MeSH secundário: Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/terapia
Metanálise como Assunto
Projetos de Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009821


  5 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406059
[Au] Autor:Alawamlh OAH; Goueli R; Lee RK
[Ad] Endereço:Department of Urology, Weill Medical College of Cornell University, James Buchanan Brady Foundation, New York, NY, USA.
[Ti] Título:Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention.
[So] Source:Med Clin North Am;102(2):301-311, 2018 Mar.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lower urinary tract symptoms (LUTS) consist of a common set of urologic symptoms that can affect the elderly. The prevalence of LUTS is expected to rise owing to the continued increase of numbers of the elderly. Although benign prostatic hyperplasia is considered a common cause of LUTS, the broader potential causes of LUTS are myriad. A wide range of diagnostic modalities and treatments are available to manage patients with LUTS and their utilization should not be limited to the urologist.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior
Hiperplasia Prostática
Retenção Urinária
[Mh] Termos MeSH secundário: Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Hiperplasia Prostática/complicações
Retenção Urinária/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  6 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240336
[Au] Autor:Allchorne P; Green J
[Ti] Título:Identifying Unmet Care Needs of Patients with Prostate Cancer To Assist with Their Success in Coping.
[So] Source:Urol Nurs;36(5):224-32, 2016 Sep-Oct.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the United Kingdom, our Health Needs Assessment survey return rate of 42% identified unmet needs in subjects with prostate cancer. Subjects reported the greatest unmet need was related to erectile dysfunction. Other unmet needs were related to incontinence, tiredness, hot flashes, lower urinary tract symptoms, rectal bleeding, and relationship issues.
[Mh] Termos MeSH primário: Adaptação Psicológica
Determinação de Necessidades de Cuidados de Saúde
Neoplasias da Próstata/enfermagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Disfunção Erétil
Fadiga
Hemorragia Gastrointestinal
Fogachos
Seres Humanos
Relações Interpessoais
Sintomas do Trato Urinário Inferior
Masculino
Meia-Idade
Reto
Inquéritos e Questionários
Reino Unido
Incontinência Urinária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  7 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28979650
[Au] Autor:Touzani MA; Yddoussalah O
[Ad] Endereço:Université Mohammed V, Faculté de Médecine et de Pharmacie de Rabat, Hopital Ibn Sina, Service d'Urologie B, Rabat, Maroc.
[Ti] Título:[Urethral ectropion may hide a carcinoma!]
[Ti] Título:Un ectropion urétral peut cacher un carcinome!.
[So] Source:Pan Afr Med J;27:249, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:The incidence of female urethral cancer is rare and accounts for 0.02% of all women's cancers. It is dominated by epidermoid carcinoma, which most commonly develops in the distal portion of the urethra, extending to inguinal lymph nodes. The diagnosis is confirmed in the distal forms on the basis of uretrocystoscopy with biopsy. Abdominopelvic MRI allows to determine tumor extension as well as its infiltration into tissues and peri-urethral organs. As in superficial tumors of the distal urethra, simple circumferential resection of the urethra associated with resection of the adjacent portion of the anterior surface of the vagina is sufficient. We here report the case of a 59-year old diabetic and hypertensive female patient presenting for irritative lower urinary tract symptoms, associated with vulvar mass. Clinical examination showed mucosal ectropion extending from the urethral meatus associated with extensive local inflammation. The patient underwent wide excision of the ectropion which was diagnosed as squamous cell carcinoma. Abdominopelvic MRI was normal.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/diagnóstico
Sintomas do Trato Urinário Inferior/etiologia
Uretra/patologia
Neoplasias Uretrais/diagnóstico
[Mh] Termos MeSH secundário: Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/cirurgia
Feminino
Seres Humanos
Meia-Idade
Uretra/cirurgia
Neoplasias Uretrais/patologia
Neoplasias Uretrais/cirurgia
Neoplasias Vulvares/diagnóstico
Neoplasias Vulvares/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171006
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.249.13260


  8 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28952690
[Au] Autor:Govorov AV; Vasilyev AO; Pushkar DY
[Ad] Endereço:Department of Urology, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia.
[Ti] Título:[Efficacy of tamsulosin for treating lower urinary tract symptoms in patients with advanced prostate cancer].
[So] Source:Urologiia;(4):37-41, 2017 Sep.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:RELEVANCE: From the moment of their first use to the present day, -adrenoblockers remain the most popular medication in urology. Indications for their clinical use for various pathological conditions are constantly expanding. AIM: To compare the efficacy of androgen deprivation therapy (ADT) alone and ADT with concomitant use of tamsulosin in treating lower urinary tract symptoms (LUTS), and to estimate the efficacy and safety of tamsulosin in relieving voiding dysfunction symptoms in patients with advanced PCa treated for 6 months. MATERIALS AND METHODS: This paper presents data from a randomized, open, single-center trial that evaluated the efficacy and safety of tamsulosin co-administered with ADT for LUTS in patients with advanced prostate cancer. The study comprised 50 people aged below 75 years. In the first group of patients (n=25), ADT was used as a monotherapy, in the second group (n=25) ADT with concurrent administration of the -adrenoblocker. The duration of treatment was 6 months. RESULTS: Both groups showed an improvement in the severity of LUTS, decrease in the total I-PSS score and residual urine volume and increase in the urinary flow rate. At the same time, co-administration of ADT and -adrenoblocker resulted in greater and faster relief of LUTS than using ADT alone. There were no significant side effects in any of the groups. CONCLUSIONS: Co-administration of ADT and the -blocker is an effective and safe treatment for advanced prostate cancer in patients with LUTS.
[Mh] Termos MeSH primário: Antagonistas de Receptores Adrenérgicos beta 1/uso terapêutico
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Neoplasias da Próstata/tratamento farmacológico
Sulfonamidas/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/uso terapêutico
Quimioterapia Combinada
Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Neoplasias da Próstata/complicações
Neoplasias da Próstata/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-1 Receptor Antagonists); 0 (Androgen Antagonists); 0 (Sulfonamides); G3P28OML5I (tamsulosin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  9 / 1780 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28845952
[Au] Autor:Korneev IA
[Ad] Endereço:Department of Urology, First Pavlov State Medical University of St. Peterburg of Minzdrav of Russia, St. Petersburg, Russia.
[Ti] Título:[Russian experience with Vitaprost Forte suppositories in patients with lower urinary tract symptoms and benign prostatic hyperplasia: comparative analysis of studies].
[So] Source:Urologiia;(3):138-144, 2017 Jul.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews the domestic studies showing the efficacy and safety of suppositories containing prostate extract (Samprost substance) Vitaprost Forte in treating men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The data obtained by Russian specialists confirm the effectiveness of Vitaprost Forte suppositories in managing patients with moderate LUTS and infravesical obstruction caused by BPH to reduce dysuria, improve the quality of life and normalize urodynamic parameters.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Peptídeos/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Avaliação Pré-Clínica de Medicamentos
Seres Humanos
Masculino
Peptídeos/administração & dosagem
Peptídeos/farmacologia
Supositórios
Resultado do Tratamento
Micção/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Peptides); 0 (Suppositories); 0 (Vitaprost)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  10 / 1780 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28829208
[Au] Autor:Thomas D; Chughtai B; Kini M; Te A
[Ad] Endereço:a Department of Urology , Weill Cornell Medicine-New York Presbyterian , New York , NY , USA.
[Ti] Título:Emerging drugs for the treatment of benign prostatic hyperplasia.
[So] Source:Expert Opin Emerg Drugs;22(3):201-212, 2017 Sep.
[Is] ISSN:1744-7623
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Benign prostatic hyperplasia (BPH) is a common condition affecting over 50% of men as they reach their 5 decade of life. This leads to a number of sequelae such as lower urinary tract symptoms, urinary retention and a decrease in quality of life. Currently, the available treatments for BPH are alpha blockers and 5-alpha reductase inhibitors. Clinical studies have demonstrated these medical options are effective in alleviating a patient's symptoms, however there are a number of side effects. There is a paucity of information regarding long-term use of these medications. The purpose of this review is to identify potential and emerging medications for the treatment of BPH. Areas covered: Articles used in this review were retrieved from Pubmed, Google and through searching the PharmaProjects database over the last 10 years, giving the reader an in-depth knowledge about the current pharmacological agents available and other potential treatments for BPH. Expert opinion: The new paradigm of BPH treatment depends on addressing a patient's specific constellation of symptoms. This allows to tailor therapy of increasing efficacy and reduce adverse events that our patients have by increasing dosage.
[Mh] Termos MeSH primário: Desenho de Drogas
Hiperplasia Prostática/tratamento farmacológico
Qualidade de Vida
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Seres Humanos
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Hiperplasia Prostática/fisiopatologia
Retenção Urinária/tratamento farmacológico
Retenção Urinária/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170823
[St] Status:MEDLINE
[do] DOI:10.1080/14728214.2017.1369953



página 1 de 178 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde